Literature DB >> 8831595

Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis.

A Ginès1, G Fernández-Esparrach, A Monescillo, C Vila, E Domènech, R Abecasis, P Angeli, L Ruiz-Del-Arbol, R Planas, R Solà, P Ginès, R Terg, L Inglada, P Vaqué, F Salerno, V Vargas, G Clemente, J C Quer, W Jiménez, V Arroyo, J Rodés.   

Abstract

BACKGROUND & AIMS: Paracentesis associated with plasma expanders is widely used for the treatment of ascites in cirrhosis. This study investigated the clinical importance of paracentesis-induced-circulatory dysfunction and compared the efficacy of albumin, dextran 70, and polygeline in preventing this complication.
METHODS: A total of 289 cirrhotic patients with ascites were randomized to treatment by total paracentesis plus intravenous albumin (97 patients), dextran 70 (93 patients), or polygeline (99 patients). Postparacentesis circulatory dysfunction was defined as an increase in plasma renin activity on the sixth day after paracentesis of more than 50% of the pretreatment value to a level > 4 ng.mL-1.h-1.
RESULTS: Postparacentesis circulatory dysfunction occurred more frequently in patients treated with dextran 70 (34.4%; P = 0.018) or polygeline (37.8%; P = 0.004) than in those receiving albumin (18.5%). The plasma expander used and the volume of ascites removed were independent predictors of this complication. Postparacentesis circulatory dysfunction persisted during follow-up and was associated with a shorter time to first readmission (1.3 +/- 0.5 vs. 3.5 +/- 0.8 months, median +/- SEM; P = 0.03) and shorter survival (9.3 +/- 4.2 vs. 16.9 +/- 4.3 months; P = 0.01). Creatinine and sodium levels in serum, and Child-Pugh score at inclusion, and postparacentesis circulatory dysfunction were independent predictors of survival.
CONCLUSIONS: Postparacentesis circulatory dysfunction is not spontaneously reversible and is associated with a shorter time to first readmission and shorter survival. Albumin is the best plasma expander to prevent this complication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8831595     DOI: 10.1016/s0016-5085(96)70068-9

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  98 in total

1.  Is there still a need for albumin infusions to treat patients with liver disease?

Authors:  P Ginès; V Arroyo
Journal:  Gut       Date:  2000-05       Impact factor: 23.059

2.  Clinical practice guidelines for the use of albumin: results of a drug use evaluation in a Paris hospital. Tenon Hospital Paris.

Authors:  I Debrix; D Combeau; F Stephan; A Benomar; A Becker
Journal:  Pharm World Sci       Date:  1999-02

Review 3.  The hepatorenal syndrome.

Authors:  L Dagher; K Moore
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

Review 4.  Hepatorenal syndrome: Update on diagnosis and treatment.

Authors:  Olga Baraldi; Chiara Valentini; Gabriele Donati; Giorgia Comai; Vania Cuna; Irene Capelli; Maria Laura Angelini; Maria Ilaria Moretti; Andrea Angeletti; Fabio Piscaglia; Gaetano La Manna
Journal:  World J Nephrol       Date:  2015-11-06

5.  Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites.

Authors:  G Nasr; A Hassan; S Ahmed; A Serwah
Journal:  J Cardiovasc Dis Res       Date:  2010-07

Review 6.  Renal dysfunction in cirrhosis: diagnosis, treatment and prevention.

Authors:  Elaine Yeung; Elaine Yong; Florence Wong
Journal:  MedGenMed       Date:  2004-12-02

7.  Guidelines on the management of ascites in cirrhosis.

Authors:  K P Moore; G P Aithal
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

8.  Treatment of refractory ascites.

Authors:  Praveena G Velamati; H Franklin Herlong
Journal:  Curr Treat Options Gastroenterol       Date:  2006

Review 9.  Clinical use of albumin.

Authors:  Paolo Caraceni; Manuel Tufoni; Maria Elena Bonavita
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 10.  Clinical use of albumin in hepatology.

Authors:  Matteo Garcovich; Maria Assunta Zocco; Antonio Gasbarrini
Journal:  Blood Transfus       Date:  2009-10       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.